RANEXA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, France, Hong Kong SAR China, Ireland, Italy, Lithuania, New Zealand, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug RANEXA contains one active pharmaceutical ingredient (API):

1	Ranolazine UNII A6IEZ5M406 - RANOLAZINE
	Ranolazine may have some antianginal effects by inhibition of the late sodium current in cardiac cells. This reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload. Ranolazine, via its action to decrease the late sodium current, is considered to reduce these intracellular ionic imbalances during ischaemia. This reduction in cellular calcium overload is expected to improve myocardial relaxation and thereby decrease left ventricular diastolic stiffness.
	Read more about Ranolazine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RANEXA Prolonged-release tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EB18	Ranolazine	C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1361652, 1361674, 1361685, 1405550, 1405561, 1405572, 1405583, 1405594, 1405606
ES	Centro de información online de medicamentos de la AEMPS	08462001, 08462003, 08462005
FR	Base de données publique des médicaments	60922794, 63170891, 64679592
GB	Medicines & Healthcare Products Regulatory Agency	149980, 149987, 149990, 375322, 377000, 377002, 377004, 381645, 381647, 381649
HK	Department of Health Drug Office	63607, 63608, 63609
IE	Health Products Regulatory Authority	43250, 43252, 43254, 43262, 43263
IT	Agenzia del Farmaco	038917011, 038917023, 038917035, 038917047, 038917050, 038917062, 038917074, 038917086, 038917098, 038917100, 038917112, 038917124
LT	Valstybinė vaistų kontrolės tarnyba	1033655, 1033656, 1033657, 1033658, 1033659, 1033660, 1056094, 1056095, 1056096, 1056097, 1056098, 1056099
NZ	Medicines and Medical Devices Safety Authority	17366, 17384, 17385
PL	Rejestru Produktów Leczniczych	100145586, 100214910, 100214927
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W55083001, W55083002, W55083003, W55083004, W55084001, W55084002, W55084003, W55084004, W55085001, W55085002, W55085003, W55085004
SG	Health Sciences Authority	14861P, 14862P, 14863P
US	FDA, National Drug Code	43353-880, 61958-1003, 61958-1004